@FierceMedDev: Only a few weeks left to submit your nominations for the 15 fiercest private device developers. Survey | Follow @FierceMedDev
> A U.S. District Court judge in Texas has approved ArthroCare's $74 million settlement in a shareholder lawsuit that alleged falsely inflated share prices. Story
> NinePoint Medical gained a CE mark to use its NVisionVLE imaging system to diagnose mucosa and submucosa diseases, following an earlier FDA 510(k) clearance. Plans call for launching the product commercially in 2013. Release
> InSite Medical Technologies has raised new funding. The Saratoga, CA company makes medical devices that deliver epidural anesthesia. Item
> Ortho Clinical Diagnostics has gained a CE mark for a new diagnostic blood test designed to measure levels of vitamin D2 and D3 in the blood. Story
> Beacon Endoscopic is pursuing a limited market launch of its BNX fine needle aspiration tech for use with endoscopic ultrasound and endoscopic bronchial ultrasound, following FDA clearance in 2010 and a CE mark in January. Release
Biotech News
@FierceBiotech: Complete Genomics axes 55 staffers, hires financial adviser to aid in exploring "strategic alternatives." Story | Follow @FierceBiotech
@JohnCFierce: Merck may be better dumping sarcomas and focusing on other tumor types in the clinic. | Follow @JohnCFierce
@RyanMFierce: With the FDA shunning Merck's ridaforolimus bid, Ariad looks pretty smart for front-ending its licensing terms with Merck on the cancer drug. | Follow @RyanMFierce
> ASCO Highlights: Top stories from this year's meeting. Report
> Chinese scientist convicted of stealing Merck's experimental drugs. News
> Merck KGaA and Dr. Reddy's partner on a slate of antibody biosims. Story
> FDA hits trap door button on Merck's weak ridaforolimus bid. Article
Pharma News
@FiercePharma: Is the whole morning-after contraceptive fight based on a misunderstanding about how they work?--NYT. Report | Follow @FiercePharma
> Study finds Roche's Actemra bests Abbott's blockbuster Humira. News
> Geneva workers propose scaleback at Merck Serono HQ. Report
> U.K. pharma balks at value-based pricing ideas. More
Drug Delivery News
@DamianFierce: Zogenix is moving forward with its DosePro drug delivery platform, filing an IND for a new anti-psychotic. More | Follow @DamianFierce
> FDA wants more info on pen delivery for Amylin's Bydureon. Story
> At ASCO, unique delivery makes TDM-1 a standout. Item
> Aptar buys injectable delivery company for $207M. News
> MIT: DNA origami could safely deliver RNAi treatment. Article
Biomarkers News
> DNA tracking responses to cancer treatment. More
> A blood test for schizophrenia? Item
> Parkinson's disease gene cluster marks early diagnosis. Story
> Teens' low-fiber diets expand bellies, disease risks. Article
And Finally... Amylin Pharmaceuticals says FDA officials want data regarding a pen-delivery device designed to be used with the company's recently-approved, long-acting diabetes drug Bydureon. Story